{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:55:19Z","timestamp":1781643319106,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Port Said University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid carcinoma is a common tumor affecting the Egyptian population accounting for 2% of newly diagnosed cases of cancer in Egypt yearly and constituting 7.73% of 5 year prevalence in Egypt. Stomatin-Like Protein 2 (SLP-2) and Trophoblast Cell Surface Antigen 2 (TROP-2) antibodies are both expressed in some types of thyroid carcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate immunohistochemical expression of SLP-2 and TROP-2 in papillary thyroid carcinoma and other thyroid lesions, assess association of both immunohistochemical markers with variable demographic and histopathological parameters and assess the diagnostic utility of both markers in thyroid carcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and methods<\/jats:title>\n                    <jats:p>The current study is a cross-sectional study with analytical component, performed in the Pathology laboratory of Suez Canal University Hospital on 144 samples of formalin fixed paraffin embedded blocks of thyroid cases, including 79 cases of PTC and 65 cases of other thyroid lesions during the period from January 2016 to May 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SLP-2 and TROP-2 have shown positive expression in 91.1% and 82.3% respectively in PTC cases. Compared to positive expressions in 38.5% and 7.7% respectively in other thyroid cases. The positivity of both markers has a statistically significant association with PTC cases, compared to other thyroid lesions p-value\u2009&lt;\u20090.05). The sensitivity of combined positively expressed markers is 79.75%, specificity is 98.46%, positive predictive value is 98.44, the negative predictive value is 80% and the test accuracy is raised to 88.19 for discrimination between PTC and other thyroid lesions. There was no statistically significant association between all histopathological parameters and the expression of SLP-2 and TROP-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SLP-2 and TROP-2 may be promising diagnostic markers of PTC carcinoma. Further studies are needed to fully evaluate the prognostic significance of SLP-2 and TROP-2 expression in PTC and other thyroid lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13000-026-01772-0","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:05:40Z","timestamp":1773727540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunohistochemical expression of Stomatin-Like protein 2 and trophoblast cell surface antigen 2 in papillary thyroid carcinoma in comparison to other thyroid lesions"],"prefix":"10.1186","volume":"21","author":[{"given":"Ahmed A.","family":"Elmetwally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa H.","family":"Khashaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba M.","family":"Wagih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-9291","authenticated-orcid":false,"given":"Azza H. M.","family":"Zidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayada S.","family":"Farrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"3","key":"1772_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1772_CR2","doi-asserted-by":"crossref","unstructured":"Singh Ospina N, I\u00f1iguez-Ariza NM, Castro MR. Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. BMJ. 2020;368. [cited 2022 Oct 8] Available from: https:\/\/www.bmj.com\/content\/368\/bmj.l6670","DOI":"10.1136\/bmj.l6670"},{"key":"1772_CR3","doi-asserted-by":"crossref","unstructured":"Vella C, Baldacchino S, Formosa R, Vassallo J. The Utility of Galectin-3 and HBME-1 Immunohistochemical Expression in Thyroid Cancer in the Maltese Population. Endocrines 2022, Vol 3, Pages 225\u2013239. 2022 ;3(2):225\u201339. [cited 2023 Jan 9] Available from: https:\/\/www.mdpi.com\/2673-396X\/3\/2\/21\/htm.","DOI":"10.3390\/endocrines3020021"},{"key":"1772_CR4","doi-asserted-by":"crossref","unstructured":"Zhou C, Li Y, Wang G, Niu W, Zhang J, Wang G et al. Enhanced SLP-2 promotes invasion and metastasis by regulating Wnt\/\u03b2-catenin signal pathway in colorectal cancer and predicts poor prognosis. Pathol Res Pract. 2019 ;215(1):57\u201367. [cited 2024 Jun 20] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30389319\/.","DOI":"10.1016\/j.prp.2018.10.018"},{"key":"1772_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.placenta.2020.07.008","volume":"100","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li BY, Fu LJ, Adu-Gyamfi EA, Xu BR, Liu TH, et al. Stomatin-like protein 2 (SLP2) regulates the proliferation and invasion of trophoblast cells by modulating mitochondrial functions. Placenta. 2020;100:13\u201323.","journal-title":"Placenta"},{"key":"1772_CR6","doi-asserted-by":"crossref","unstructured":"Chen J, Wang D, Xu R, Yao T, Guo Y, Liu Q et al. SLP-2 regulates the generation of reactive oxygen species and the ERK pathway to promote papillary thyroid carcinoma motility and angiogenesis. Tissue Cell. 2023 ;80. [cited 2024 Jun 20] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36527788\/.","DOI":"10.1016\/j.tice.2022.101997"},{"key":"1772_CR7","doi-asserted-by":"publisher","unstructured":"Chao D, Ariake K, Sato S, Ohtsuka H, Takadate T, Ishida M et al. Stomatin-like protein 2 induces metastasis by regulating the expression of a rate-limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Oncol Rep. 2021 ;45(6):1\u201310. [cited 2024 Jun 20] Available from: http:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/or.2021.8041\/abstract","DOI":"10.3892\/or.2021.8041\/abstract"},{"key":"1772_CR8","doi-asserted-by":"crossref","unstructured":"Qin C, Wang Y, Zhao B, Li Z, Li T, Yang X et al. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Cell Death Dis. 2023 ;14(3). [cited 2024 Jun 20]Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36906621\/","DOI":"10.1038\/s41419-023-05711-5"},{"key":"1772_CR9","doi-asserted-by":"publisher","unstructured":"Turan Z, Erk\u0131l\u0131\u00e7 S. TROP2: a potential marker in diagnosis of thyroid neoplasms. Ir J Med Sci. 2023 ;192(1):99\u2013103. [cited 2024 Jun 21] Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s11845-022-02976-1","DOI":"10.1007\/s11845-022-02976-1"},{"key":"1772_CR10","unstructured":"Abdulwahhab OS, Latif H, Kadhim TJ, IMMUNOHISTOCHEMICAL EXPRESSION OF, TROP2 AND BRAV-V600E PROTEINS IN PAPILLARY THYROID CARCINOMA, HASHIMOTO\u2019S THYROIDITIS, AND GRAVE\u2019S DISEASE IN CORRELATION WITH CERTAIN CLINICO-PATHOLOGICAL PARAMETERS. Biochem Cell Arch. 2020 [cited 2024 Jun 21];20(2):4641\u20136. Available from: https:\/\/connectjournals.com\/03896.2020.20.4641\/."},{"key":"1772_CR11","doi-asserted-by":"crossref","unstructured":"Mcdougall ARA, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Trop2: from development to disease. Dev Dyn. 2015 ;244(2):99\u2013109. [cited 2024 Jun 21] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25523132\/","DOI":"10.1002\/dvdy.24242"},{"key":"1772_CR12","doi-asserted-by":"crossref","unstructured":"Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010 [cited 2024 Jun 21];9:253. Available from: https:\/\/www.researchgate.net\/publication\/46392690_Trop2_expression_contributes_to_tumor_pathogenesis_by_activating_the_ERK_MAPK_pathway","DOI":"10.1186\/1476-4598-9-253"},{"key":"1772_CR13","doi-asserted-by":"crossref","unstructured":"Sun H, Chen Q, Liu W, Liu Y, Ruan S, Zhu C et al. TROP2 modulates the progression in papillary thyroid carcinoma. J Cancer. 2021 ;12(22):6883\u201393. [cited 2024 Jun 19] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34659576","DOI":"10.7150\/jca.62461"},{"key":"1772_CR14","doi-asserted-by":"publisher","unstructured":"Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022 ;33(1):27\u201363. [cited 2022 Oct 17] Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s12022-022-09707-3","DOI":"10.1007\/s12022-022-09707-3"},{"key":"1772_CR15","unstructured":"Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE et al. AJCC Cancer Staging Manual (8th edition). Springer Int Publ Am Jt Comm Cancer. 2017;1\u2013997."},{"key":"1772_CR16","doi-asserted-by":"crossref","unstructured":"\u015etefan AE, Gologan D, Leavitt MO, Mu\u015fat S, Ple\u015fea IE, Stan LGR et al. Tissue microarrays \u2013 brief history, techniques and clinical future. Rom J Morphol Embryol. 2021 ;61(4):1077. [cited 2025 Jul 23]Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8343478\/","DOI":"10.47162\/RJME.61.4.10"},{"issue":"8","key":"1772_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00405-018-5045-x","volume":"275","author":"X Yang","year":"2018","unstructured":"Yang X, Hu Y, Shi H, Zhang C, Wang Z, Liu X, et al. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. Eur Arch Oto-Rhino-Laryngology. 2018;275(8):2127\u201334.","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"key":"1772_CR18","doi-asserted-by":"crossref","unstructured":"van Belle G. Statistical rules of thumb: second edition. Stat Rules Thumb Second Ed. 2008;1\u2013272.","DOI":"10.1002\/9780470377963"},{"key":"1772_CR19","doi-asserted-by":"crossref","unstructured":"Ma W, Xu Z, Wang Y, Li W, Wei Z, Chen T et al. A Positive Feedback Loop of SLP2 Activates MAPK Signaling Pathway to Promote Gastric Cancer Progression. Theranostics. 2018 ;8(20):5744\u201357. [cited 2024 Jun 20] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30555578\/","DOI":"10.7150\/thno.28898"},{"key":"1772_CR20","doi-asserted-by":"crossref","unstructured":"Abdou AG, Shabaan M, Abdallha R, Nabil N. Diagnostic Value of TROP-2 and CK19 Expression in Papillary Thyroid Carcinoma in Both Surgical and Cytological Specimens. Clin Pathol (Thousand Oaks, Ventur County, Calif). 2019;12. [cited 2024 Nov 1] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31384753\/","DOI":"10.1177\/2632010X19863047"},{"key":"1772_CR21","doi-asserted-by":"publisher","unstructured":"Guerra E, Trerotola M, Alberti S. Targeting Trop-2 as a Cancer Driver. 2023 [cited 2024 Jun 21]; Available from: https:\/\/doi.org\/10.1200\/JCO.23.01207","DOI":"10.1200\/JCO.23.01207"},{"issue":"4","key":"1772_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/apm.12505","volume":"124","author":"A Bartolome","year":"2016","unstructured":"Bartolome A, Boskovic S, Paunovic I, Bozic V, Cvejic D. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation. APMIS. 2016;124(4):271\u20137.","journal-title":"APMIS"},{"issue":"3","key":"1772_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/CBM-230230","volume":"39","author":"AS Attia","year":"2024","unstructured":"Attia AS, Hussein S, Sameh H, Khalil A, Waley AB, Matar I, et al. Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma. Cancer Biomarkers. 2024;39(3):211\u201321.","journal-title":"Cancer Biomarkers"},{"issue":"1","key":"1772_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/or.2013.2833","volume":"31","author":"Z Liu","year":"2014","unstructured":"Liu Z, Yang Y, Zhang Y, Ye X, Wang L, Xu G. Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-\u03b2 in thyroid cancer cells. Oncol Rep. 2014;31(1):153\u201360.","journal-title":"Oncol Rep"},{"issue":"1","key":"1772_CR25","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3126\/jpn.v8i1.19442","volume":"8","author":"HH Nesreen","year":"2018","unstructured":"Nesreen HH, Manal SZ, Mohamed AM. Diagnostic utility of trophoblastic cell surface antigen 2 immunohistochemical expression in papillary thyroid carcinoma. J Pathol Nepal. 2018;8(1):1235\u201343.","journal-title":"J Pathol Nepal"},{"key":"1772_CR26","doi-asserted-by":"crossref","unstructured":"Addati T, Achille G, Centrone M, Petroni S, Popescu O, Russo S et al. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study. Cytopathology. 2015 ;26(5):303\u201311. [cited 2024 Oct 30] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25164548\/","DOI":"10.1111\/cyt.12196"},{"key":"1772_CR27","doi-asserted-by":"crossref","unstructured":"Bychkov A, Sampatanukul P, Shuangshoti S, Keelawat S. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology. 2016 ;48(5):425\u201333. [cited 2024 Oct 30] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27311870\/","DOI":"10.1016\/j.pathol.2016.04.002"},{"key":"1772_CR28","doi-asserted-by":"crossref","unstructured":"Simms A, Jacob RP, Cohen C, Siddiqui MT. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility. Diagn Cytopathol. 2016 ;44(1):26\u201331. [cited 2024 Oct 30] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26481593\/","DOI":"10.1002\/dc.23382"},{"key":"1772_CR29","doi-asserted-by":"crossref","unstructured":"Murtezaoglu AR, Gucer H. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19. Pol J Pathol. 2017 ;68(1):1\u201310. [cited 2024 Oct 30] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28547974\/","DOI":"10.5114\/pjp.2017.67610"},{"key":"1772_CR30","doi-asserted-by":"crossref","unstructured":"Raouf SMA, Atia H, Soliman SA, Elshahidy TM, Mohamed SY. Diagnostic Utility of Immunohistochemical Markers Trop2 and CD56 in Differentiating Follicular Derived Thyroid Lesions. La Prensa Medica Argentina. 2020 ;106(6). [cited 2024 Jun 21] Available from: https:\/\/www.researchgate.net\/publication\/346437248_Diagnostic_Utility_of_Immunohistochemical_Markers_Trop2_and_CD56_in_Differentiating_Follicular_Derived_Thyroid_Lesions","DOI":"10.47275\/0032-745X-246"},{"key":"1772_CR31","doi-asserted-by":"crossref","unstructured":"Saffar H, Jahanbin B, Ameli F, Farhang F, Tavangar SM, Saffar H. Diagnostic Value of TROP2 Expression in Papillary Thyroid Carcinoma. Appl Immunohistochem Mol Morphol AIMM. 2021 ;29(3):218\u201322. [cited 2024 Oct 30] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33264108\/","DOI":"10.1097\/PAI.0000000000000886"},{"key":"1772_CR32","doi-asserted-by":"crossref","unstructured":"Zargari N, Mokhtari M. Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma. Eur Thyroid J. 2019;8(1):1\u20136. [cited 2024 Oct 30] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30800635\/","DOI":"10.1159\/000494430"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-026-01772-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01772-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01772-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:16:13Z","timestamp":1781640973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-026-01772-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1186\/s13000-026-01772-0","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and accepted by the (IRB\/IEC) institutional review board and institutional research ethics committee of PSU prior to initiation (ERN: MED (1\/6\/2023) s.no (95) PTH 904_001).The research involved no risks over researcher, sample or environment.The need for informed consent has been waived by the (IRB\/IEC) institutional review board and institutional research ethics committee of PSU.The study used human data and material (paraffin blocks) and it was adherent to the declaration of Helsinki and this was insured by (IRB\/IEC) institutional review board and institutional research ethics committee of PSU.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}